About
Kevin Fitzgerald, PhD is a biopharmaceutical research executive best identified from official sources as Chief Scientific Officer, Executive Vice President, and Head of Research at Alnylam Pharmaceuticals. He joined Alnylam in 2005, has led RNAi delivery and drug-discovery programs including inclisiran, and is named on more than 50 patents and 50 papers. He also serves on the Scientific Advisory Board of Generation Bio and as an independent board director of Ovid Therapeutics.
Areas of interest
biotechRNA interferencedrug discoverygeneticsmolecular biologyrare disease therapeuticscardiometabolic therapeutics